How to Choose a Hub Services Vendor: A Buyer's Guide

A practical framework for pharma teams evaluating patient services hub vendors: vendor archetypes, evaluation criteria, pricing models, RFP questions, and red flags.

Published July 21, 2026

Hub Services

Choosing a hub services vendor comes down to matching a vendor archetype to your brand’s needs, then testing candidates against a small set of concrete criteria: therapeutic-area experience, integration and automation capability, staffing model, data transparency, ownership stability, and pricing structure. There is no universally “best” hub — a rare-disease launch with 500 patients needs a fundamentally different partner than a rheumatology brand with 100,000. This guide walks through the vendor landscape, the criteria that separate strong programs from weak ones, and the questions worth asking before you sign.

Start with what you are actually buying

A hub program typically bundles some combination of benefit verification, prior authorization support, patient enrollment and consent, financial assistance coordination, nurse education, and adherence outreach. Before evaluating vendors, define which of these you need, at what volume, and under which benefit type — pharmacy benefit, medical benefit, or both. Medical-benefit products (infusions, provider-administered therapies) require buy-and-bill expertise and site-of-care coordination that many pharmacy-benefit-focused hubs handle poorly.

The stakes are significant: US pharmacies dispensed an estimated $293.4 billion in specialty medications in 2025, up 9.6% year over year, according to Drug Channels Institute. Nearly every one of those specialty prescriptions passes through some form of access and reimbursement workflow that a hub either accelerates or bottlenecks.

The four vendor archetypes

Hub vendors cluster into recognizable groups. Vendors below are listed alphabetically within each group — placement is descriptive, not a ranking.

Archetype	Typical strengths	Representative vendors
Distributor-affiliated hubs	Scale, integration with distribution and 3PL, established payer connectivity	CoverMyMeds (McKesson), Sonexus Access and Patient Support (Cardinal Health)
Independent full-service hubs	Dedicated patient services focus, flexible program design, often PE-backed	AssistRx, CareMetx, CareTria, Conduent, ConnectiveRx, EVERSANA, IQVIA Patient Services, UBC, Valeris
Technology-first platforms	Automation of benefit verification, prior auth, and enrollment; lower per-transaction cost	Annexus Health, Infinitus Systems, Phil, RxLightning, SamaCare
Rare-disease and pharmacy-model specialists	High-touch care teams, non-commercial or exclusive pharmacy models, orphan-drug launch experience	AnovoRx, AscellaHealth / Optime Care, Orsini

The boundaries blur in practice. Large full-service hubs license their technology, technology platforms add human services teams, and several vendors operate non-dispensing pharmacies alongside their hubs. Treat the archetypes as a starting filter, not a final classification.

Seven evaluation criteria that matter

1. Therapeutic-area and benefit-type fit

Ask for evidence of live programs in your therapeutic area and benefit type. A vendor with deep oncology medical-benefit experience may still be a poor fit for a self-administered dermatology product. Request anonymized case studies with program metrics, not just client logos.

2. Integration and automation capability

Modern hubs differentiate on electronic benefit verification (eBV), electronic prior authorization (ePA), and e-enrollment embedded in prescriber workflows. Ask what percentage of benefit verifications complete electronically without a phone call, and how the vendor connects to EHRs and e-prescribing networks. The industry is consolidating around this capability: CoverMyMeds acquired e-enrollment platform RxLightning and prior-auth startup FastAuth in June 2025, and CareTria’s 2026 relaunch was built around its acquisition of eBlu Solutions, a provider-facing benefit investigation platform.

3. Staffing model and turnover

Hubs are operationally intensive. Understand whether your program gets dedicated or shared agents, where teams sit, what training covers, and what agent turnover looks like. High turnover on a rare-disease program — where case managers build relationships with individual patients — is a quality problem, not just an HR statistic.

4. Data, reporting, and transparency

You should be able to see enrollment-to-fill conversion, time-to-therapy, prior authorization approval rates, and drop-off points in near real time. Ask to see the actual reporting portal during diligence, and clarify who owns program data if you switch vendors.

5. Compliance posture

Hub programs sit close to several legal tripwires: the Anti-Kickback Statute, HIPAA, and state-level patient communication rules. Evaluate the vendor’s compliance infrastructure, audit history, and how it firewalls manufacturer-funded support from anything resembling improper inducement.

6. Ownership stability

The hub market is consolidating rapidly — the Mercalis–PharmaCord merger that created Valeris closed in May 2025, and CareMetx acquired Cencora’s legacy Lash Group hub operations in April 2026. Ownership changes mid-contract can mean leadership churn, platform migrations, or shifting priorities. Ask who owns the vendor, how long the current sponsor has held it, and what contractual protections you have if the company is sold.

7. Pricing structure

Common models include per-enrolled-patient fees, per-transaction pricing (per BV, per PA), dedicated FTE pricing, and hybrid arrangements. None is inherently better; the risk is mismatch. Per-patient pricing on a fast-growing brand can escalate quickly, while FTE pricing on a low-volume rare-disease program may leave you paying for idle capacity. Model costs at three volume scenarios before comparing bids.

Questions to ask in the RFP

What percentage of benefit verifications on comparable programs complete electronically, and what is the median turnaround for the remainder?
What is median time from enrollment to first fill on your three most comparable programs?
Which EHR, e-prescribing, and specialty pharmacy integrations are live today, not on the roadmap?
Who will staff our program, at what dedication level, and what is annualized turnover for that team?
What happens to our data, patient records, and phone numbers if we terminate?
Who owns your company, and what change-of-control provisions will you accept in the contract?
Can we speak with two current clients of comparable size and one former client?

Red flags

Reluctance to share program-level performance metrics or client references.
“Everything for everyone” positioning with no evidence of depth in your therapeutic area.
Reporting delivered as monthly slide decks rather than live dashboards.
Pricing proposals that resist volume-scenario modeling.
No clear answer on data ownership and transition support at contract end.

The bottom line

Shortlist three to five vendors across at least two archetypes, force them through the same scenario-based RFP, and weight your scoring toward the two or three criteria your brand genuinely cannot compromise on — for a rare-disease launch, that is usually staffing quality and therapeutic experience; for a high-volume retail specialty brand, it is usually automation rates and per-transaction economics. Then verify claims through reference calls and a site visit before contracting. A hub is one of the most operationally entangled vendor relationships a brand team will manage; an extra month of diligence is cheaper than a mid-launch transition.